Ed Sturrock is a professor of chemical and systems biology in the Department of Integrative Biomedical Sciences at the University of Cape Town (UCT). He received his PhD at UCT in 1994 working on the synthesis and metabolism of bilirubin. Following his PhD, he went on to do a postdoctoral fellowship at Harvard Medical School where he started his research on angiotensin-converting enzyme (ACE). In 2003 he was awarded a Wellcome Trust International Senior Research Fellowship. His research interests include: structure-function aspects of ACE; cardiovascular drug discovery; and the molecular machinery involved in the processing of membrane-anchored proteins. He has made significant contributions to the national and international scientific communities. He is a Fellow and past council member of the Royal Society of South Africa, a Fellow of the University of Cape Town, a member of the Academy of Science of South Africa, a visiting professor at the University of Bath, and has a National Research Foundation B1 rating. He has published over 110 papers in peer-reviewed international journals and four patents. Together with colleagues from the UK and USA, he founded AngioDesign (UK) Ltd, a spinout company that focuses on the rational design of enhanced next-generation drugs for proven disease targets, such as ACE and NEP.